Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

SURMOUNT-OSA Study 2 involved patients who needed PAP therapy and in this group tirzepatide achieved an average AHI reduction of 30.4 events per hour, versus 6.0 for the control group. Treatment ...

If anything could threaten Novo Nordisk's ambitions in this area, it is likely to be tirzepatide. In SURMOUNT-1 ... Novo Nordisk's STEP trial programme for Wegovy revealed an average reduction ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Larger outsourcing facilities, which are FDA-regulated and can create prescription-specific compounded drugs as well as bulk orders, must cease compounding, distributing or dispensing tirzepatide ...

Opens in a new tab or window Last week marked the FDA's deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next.

Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking strategic partnership with Eli Lilly and Company (Lilly) to initiate a five-year ...